EL7.AI
StocksMediumUpdated•Originally published 28 September 2026•Updated 28 September 2026•
1 min read

Kodiak Sciences Eye Drug Meets Phase 3 Goals, Matching Competitor Regeneron

Key Facts

1Kodiak Sciences announced positive data from its Phase 3 DAYBREAK study for its eye treatments Zenkuda and tabirafusp-ted.
2Study results showed the drug's efficacy is on par with competitor Regeneron's medicine.

Kodiak Sciences announced positive data from its Phase 3 DAYBREAK study for its eye treatments Zenkuda and tabirafusp-ted. Reuters reported that the study results showed the drug's efficacy is on par with competitor Regeneron's medicine, as the company seeks to establish clinical non-inferiority to support regulatory approval.

KOD was trading at $89.92 on September 28, 2026, surging 177.96% following the release of Phase 3 trial data for its wet age-related macular degeneration program. This price action follows a close of $32.35 on September 25, 2026, reflecting a significant market reaction to the clinical milestone.

Open on chart